{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:31:57Z","timestamp":1793316717376,"version":"4.5.0"},"reference-count":117,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T00:00:00Z","timestamp":1712016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Anemia is common in cancer patients and impacts on quality of life and prognosis. It is typically multifactorial, often involving different pathophysiological mechanisms, making treatment a difficult task. In patients undergoing active anticancer treatments like chemotherapy, decreased red blood cell (RBC) production due to myelosuppression generally predominates, but absolute or functional iron deficiency frequently coexists. Current treatments for chemotherapy-related anemia include blood transfusions, erythropoiesis-stimulating agents, and iron supplementation. Each option has limitations, and there is an urgent need for novel approaches. After decades of relative immobilism, several promising anti-anemic drugs are now entering the clinical scenario. Emerging novel classes of anti-anemic drugs recently introduced or in development for other types of anemia include activin receptor ligand traps, hypoxia-inducible factor-prolyl hydroxylase inhibitors, and hepcidin antagonists. Here, we discuss their possible role in the treatment of anemia observed in patients receiving anticancer therapies.<\/jats:p>","DOI":"10.3389\/fonc.2024.1380358","type":"journal-article","created":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T01:02:09Z","timestamp":1712019729000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":38,"title":["Anemia in patients receiving anticancer treatments: focus on novel therapeutic approaches"],"prefix":"10.3389","volume":"14","author":[{"given":"Claudia","family":"Bozzini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Busti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Marchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Vianello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Cerchione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Girelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2004.06.019","article-title":"The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients","volume":"40","author":"Ludwig","year":"2004","journal-title":"Eur J Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-019-04938-3","article-title":"Iron deficiency during first-line chemotherapy in metastatic cancers: a prospective epidemiological study","volume":"28","author":"Saint","year":"2020","journal-title":"Support Care Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.112813","article-title":"The role of inflammation, iron, and nutritional status in cancer-related anemia: results of a large, prospective, observational study","volume":"100","author":"Maccio","year":"2015","journal-title":"Haematologica"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004017","article-title":"How I treat cancer-associated anemia","volume":"136","author":"Gilreath","year":"2020","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","first-page":"102837","DOI":"10.1016\/j.critrevonc.2019.102837","article-title":"Recent update in the pathogenesis and treatment of chemotherapy and cancer induced anemia","volume":"145","author":"Abdel-Razeq","year":"2020","journal-title":"Crit Rev oncology\/hematol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3390\/ph11040094","article-title":"Anemia and iron deficiency in cancer patients: role of iron replacement therapy","volume":"11","author":"Busti","year":"2018","journal-title":"Pharm (Basel)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1182\/blood-2018-06-856500","article-title":"Anemia of inflammation","volume":"133","author":"Weiss","year":"2019","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"100861","DOI":"10.1016\/j.mam.2020.100861","article-title":"The changing landscape of iron deficiency","volume":"75","author":"Camaschella","year":"2020","journal-title":"Mol Aspects Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"593","DOI":"10.2147\/JEP.S262349","article-title":"Experimental drugs for chemotherapy- and cancer-related anemia","volume":"13","author":"Madeddu","year":"2021","journal-title":"J Exp Pharmacol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3319","article-title":"A prospective multicenter phase II study on the efficacy and safety of dasatinib in the treatment of metastatic gastrointestinal stromal tumors failed by imatinib and sunitinib and analysis of NGS in peripheral blood","volume":"9","author":"Zhou","year":"2020","journal-title":"Cancer Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00086-3","article-title":"Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial","volume":"22","author":"Siena","year":"2021","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33067","article-title":"A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer","volume":"126","author":"Zhang","year":"2020","journal-title":"Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.1051","article-title":"Treatment of the immune-related adverse effects of immune checkpoint inhibitors: A review","volume":"2","author":"Friedman","year":"2016","journal-title":"JAMA Oncol"},{"key":"B14","first-page":"17","article-title":"Anemia in cancer patients: significance, epidemiology, and current therapy","volume":"16","author":"Tchekmedyian","year":"2002","journal-title":"Oncol (Williston Park)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/bmjspcare-2021-002913","article-title":"Iron deficiency in patients with cancer: a prospective cross-sectional study","author":"Luporsi","year":"2021","journal-title":"BMJ Support Palliat Care"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.19.1616","article-title":"Chemotherapy-induced anemia in adults: incidence and treatment","volume":"91","author":"Groopman","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600247","article-title":"The level of haemoglobin in anaemic cancer patients correlates positively with quality of life","volume":"86","author":"Lind","year":"2002","journal-title":"Br J Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf122","article-title":"The impact of hemoglobin levels on fatigue and quality of life in cancer patients","volume":"13","author":"Holzner","year":"2002","journal-title":"Ann Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/(ISSN)1097-0142","article-title":"Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review","volume":"91","author":"Caro","year":"2001","journal-title":"Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.2.601","article-title":"Management of anemia in patients receiving chemotherapy","volume":"20","author":"Waters","year":"2002","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"iv271","DOI":"10.1093\/annonc\/mdy323","article-title":"Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines","volume":"29","author":"Aapro","year":"2018","journal-title":"Ann Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1055\/s-0043-1771445","article-title":"Practical clinical consensus guidelines for the management of cancer associated anemia in low- and middle-income countries","volume":"12","author":"Parikh","year":"2023","journal-title":"South Asian J Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018030387","article-title":"Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO\/ASH clinical practice guideline update","volume":"3","author":"Bohlius","year":"2019","journal-title":"Blood Adv"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2019.06.018","article-title":"Treatment options for anemia in the elderly","volume":"58","author":"Busti","year":"2019","journal-title":"Transfus Apher Sci"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-020-02417-w","article-title":"Practical implications of the 2019 Nobel Prize in Physiology or Medicine: from molecular adaptation to hypoxia to novel anti-anemic drugs in the clinic","volume":"15","author":"Busti","year":"2020","journal-title":"Intern Emerg Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e576","DOI":"10.1097\/HS9.0000000000000576","article-title":"Innovative treatments for rare anemias","volume":"5","author":"Cappellini","year":"2021","journal-title":"Hemasphere"},{"key":"B27","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1093\/bja\/aet068","article-title":"Inflammatory response, immunosuppression, and cancer recurrence after perioperative blood transfusions","volume":"110","author":"Cata","year":"2013","journal-title":"Br J Anaesth"},{"key":"B28","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.atc.2004.07.004","article-title":"Risks of blood transfusion","volume":"23","author":"Goodnough","year":"2005","journal-title":"Anesthesiol Clin North Am"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e31825b35d5","article-title":"Effects of allogeneic red blood cell transfusions on clinical outcomes in patients undergoing colorectal cancer surgery: a systematic review and meta-analysis","volume":"256","author":"Acheson","year":"2012","journal-title":"Ann Surg"},{"key":"B30","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1471-2482-14-34","article-title":"Perioperative blood transfusion adversely affects prognosis after resection of lung cancer: a systematic review and a meta-analysis","volume":"14","author":"Luan","year":"2014","journal-title":"BMC Surg"},{"key":"B31","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ygyno.2014.11.009","article-title":"Perioperative blood transfusion in gynecologic oncology surgery: analysis of the National Surgical Quality Improvement Program Database","volume":"136","author":"Prescott","year":"2015","journal-title":"Gynecol Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.9185","article-title":"Clinical practice guidelines from the AABB: red blood cell transfusion thresholds and storage","volume":"316","author":"Carson","year":"2016","journal-title":"JAMA: J Am Med Assoc"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00280-007-0561-1","article-title":"A randomized trial of anemia correction with two different hemoglobin targets in the first-line chemotherapy of advanced gastric cancer","volume":"62","author":"Park","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.1537-2995.2007.01485.x","article-title":"A multicenter pilot-randomized controlled trial of the feasibility of an augmented red blood cell transfusion strategy for patients treated with induction chemotherapy for acute leukemia or stem cell transplantation","volume":"48","author":"Webert","year":"2008","journal-title":"Transfusion"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/j.0958-7578.2004.00477.x","article-title":"Feasibility of a restrictive red-cell transfusion policy for patients treated with intensive chemotherapy for acute myeloid leukaemia","volume":"14","author":"Jansen","year":"2004","journal-title":"Transfus Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctrv.2016.03.010","article-title":"How low should we go: A systematic review and meta-analysis of the impact of restrictive red blood cell transfusion strategies in oncology","volume":"46","author":"Prescott","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.12914","article-title":"Red blood cell transfusion: 2023 AABB international guidelines","volume":"330","author":"Carson","year":"2023","journal-title":"JAMA: J Am Med Assoc"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt118","article-title":"Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia","volume":"24","author":"Ludwig","year":"2013","journal-title":"Ann Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1804281","article-title":"Anemia of inflammation","volume":"381","author":"Ganz","year":"2019","journal-title":"New Engl J Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-286260","article-title":"Detection, evaluation, and management of iron-restricted erythropoiesis","volume":"116","author":"Goodnough","year":"2010","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.119","article-title":"Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial","volume":"22","author":"Auerbach","year":"2004","journal-title":"J Clin Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.2051","article-title":"Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha","volume":"26","author":"Pedrazzoli","year":"2008","journal-title":"J Clin Oncol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"Cd009624","DOI":"10.1002\/14651858.CD009624.pub2","article-title":"The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents","volume":"2","author":"Mhaskar","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"B44","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3109\/0284186X.2012.702921","article-title":"Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia - systematic review and meta-analysis of randomised controlled trials","volume":"52","author":"Gafter-Gvili","year":"2013","journal-title":"Acta Oncol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s12185-017-2373-3","article-title":"Modern iron replacement therapy: clinical and pathophysiological insights","volume":"107","author":"Girelli","year":"2018","journal-title":"Int J Hematol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1159\/000496967","article-title":"The role of intravenous iron in the treatment of anemia associated with cancer and chemotherapy","volume":"142","author":"Rodgers","year":"2019","journal-title":"Acta Haematol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1758835920953292","DOI":"10.1177\/1758835920953292","article-title":"Treatment of anemia in cancer patients undergoing chemotherapy with intravenous ferric carboxymaltose without erythropoiesis-stimulating agents","volume":"12","author":"Abdel-Razeq","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26376","article-title":"Efficacy and safety of ferric carboxymaltose infusion in reducing anemia in patients receiving chemotherapy for nonmyeloid Malignancies: A randomized, placebo-controlled study (IRON-CLAD)","volume":"96","author":"Makharadze","year":"2021","journal-title":"Am J Hematol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac005","article-title":"Impact of iron-deficiency management on quality of life in patients with cancer: A prospective cohort study (CAMARA study)","volume":"27","author":"Gluszak","year":"2022","journal-title":"Oncologist"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.88.11.4946","article-title":"Iron-independent induction of ferritin H chain by tumor necrosis factor","volume":"88","author":"Miller","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.10.3505","article-title":"Regulation of ferritin genes and protein","volume":"99","author":"Torti","year":"2002","journal-title":"Blood"},{"key":"B52","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Hematopoietic growth factors.2024"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-639112","article-title":"Hepcidin in the diagnosis of iron disorders","volume":"127","author":"Girelli","year":"2016","journal-title":"Blood"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-636407","article-title":"Serum hepcidin levels predict response to intravenous iron and darbepoetin in chemotherapy-associated anemia","volume":"125","author":"Steensma","year":"2015","journal-title":"Blood"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003091","article-title":"Efficacy of intravenous iron treatment for chemotherapy-induced anemia: A prospective Phase II pilot clinical trial in South Korea","volume":"17","author":"Jang","year":"2020","journal-title":"PloS Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2018-0783","article-title":"Provisional standardization of hepcidin assays: creating a traceability chain with a primary reference material, candidate reference method and a commutable secondary reference material","volume":"57","author":"Diepeveen","year":"2019","journal-title":"Clin Chem Lab medicine: CCLM\/FESCC"},{"key":"B57","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1373\/clinchem.2016.256768","article-title":"Toward worldwide hepcidin assay harmonization: identification of a commutable secondary reference material","volume":"62","author":"van der Vorm","year":"2016","journal-title":"Clin Chem"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.11.2865","article-title":"Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial","volume":"19","author":"Littlewood","year":"2001","journal-title":"J Clin Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/94.16.1211","article-title":"Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy","volume":"94","author":"Vansteenkiste","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"B60","doi-asserted-by":"publisher","first-page":"CD003407","DOI":"10.1002\/14651858.CD003407.pub5","article-title":"Erythropoietin or darbepoetin for patients with cancer","volume":"12","author":"Tonia","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-011637","article-title":"Comparative effectiveness and safety of erythropoiesis-stimulating agents (biosimilars vs originators) in clinical practice: a population-based cohort study in Italy","volume":"7","author":"Trotta","year":"2017","journal-title":"BMJ Open"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djj189","article-title":"Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients","volume":"98","author":"Bohlius","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60502-X","article-title":"Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials","volume":"373","author":"Bohlius","year":"2009","journal-title":"Lancet"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.09.008","article-title":"Erythropoietin stimulates tumor growth via ephB4","volume":"28","author":"Pradeep","year":"2015","journal-title":"Cancer Cell"},{"key":"B65","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/j.1749-6632.2009.04569.x","article-title":"Complex and context dependent regulation of hematopoiesis by TGF-beta superfamily signaling","volume":"1176","author":"Soderberg","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"B66","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.exphem.2012.12.002","article-title":"Stromal cell-mediated inhibition of erythropoiesis can be attenuated by Sotatercept (ACE-011), an activin receptor type II ligand trap","volume":"41","author":"Iancu-Rubin","year":"2013","journal-title":"Exp Hematol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001057","article-title":"Lack of Gdf11 does not improve anemia or prevent the activity of RAP-536 in a mouse model of \u03b2-thalassemia","volume":"134","author":"Guerra","year":"2019","journal-title":"Blood"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001983","article-title":"GDF11 is not the target of luspatercept","volume":"134","author":"Camaschella","year":"2019","journal-title":"Blood"},{"key":"B69","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/nm.3468","article-title":"An activin receptor IIA ligand trap corrects ineffective erythropoiesis in beta-thalassemia","volume":"20","author":"Dussiot","year":"2014","journal-title":"Nat Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-511238","article-title":"Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine beta-thalassemia","volume":"123","author":"Suragani","year":"2014","journal-title":"Blood"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12838","article-title":"An activin receptor IIA ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin","volume":"165","author":"Carrancio","year":"2014","journal-title":"Br J Haematol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0711263105","article-title":"A soluble activin type IIA receptor induces bone formation and improves skeletal integrity","volume":"105","author":"Pearsall","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.081208","article-title":"Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women","volume":"24","author":"Ruckle","year":"2009","journal-title":"J Bone Miner Res"},{"key":"B74","article-title":"Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss","volume":"12","author":"Raje","year":"2010","journal-title":"Curr Opin Mol Ther"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23732","article-title":"A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers","volume":"89","author":"Attie","year":"2014","journal-title":"Am J Hematol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910182","article-title":"A phase 3 trial of luspatercept in patients with transfusion-dependent \u03b2-thalassemia","volume":"382","author":"Cappellini","year":"2020","journal-title":"N Engl J Med"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-876888","article-title":"Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis","volume":"133","author":"Fenaux","year":"2019","journal-title":"Blood"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002177","article-title":"Development of luspatercept to treat ineffective erythropoiesis","volume":"5","author":"Kubasch","year":"2021","journal-title":"Blood Adv"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908892","article-title":"Luspatercept in patients with lower-risk myelodysplastic syndromes","volume":"382","author":"Fenaux","year":"2020","journal-title":"New Engl J Med"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00874-7","article-title":"Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial","volume":"402","author":"Platzbecker","year":"2023","journal-title":"Lancet"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01521-4","article-title":"Luspatercept for myelodysplastic syndromes\/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis","volume":"36","author":"Komrokji","year":"2022","journal-title":"Leukemia"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000967580.08826.11","article-title":"S167: efficacy and safety of luspatercept for the treatment of anemia in patients with myelofibrosis: results from the ace-536-mf-001 study","volume":"7","author":"Gerds","year":"2023","journal-title":"Hemasphere"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-015-2929-9","article-title":"Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies","volume":"24","author":"Raftopoulos","year":"2016","journal-title":"Support Care Cancer"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-043021-032816","article-title":"Hepcidin and iron in health and disease","volume":"74","author":"Nemeth","year":"2023","journal-title":"Annu Rev Med"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2014.00086","article-title":"Hepcidin antagonists for potential treatments of disorders with hepcidin excess","volume":"5","author":"Poli","year":"2014","journal-title":"Front Pharmacol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-245977","article-title":"Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia","volume":"115","author":"Sasu","year":"2010","journal-title":"Blood"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-09-456756","article-title":"The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys","volume":"121","author":"Schwoebel","year":"2013","journal-title":"Blood"},{"key":"B88","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13045-017-0427-x","article-title":"A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia","volume":"10","author":"Vadhan-Raj","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-559484","article-title":"Effect of the antihepcidin Spiegelmer lexaptepid on inflammation-induced decrease in serum iron in humans","volume":"124","author":"van Eijk","year":"2014","journal-title":"Blood"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13433","article-title":"Safety, pharmacokinetics and pharmacodynamics of the anti-hepcidin Spiegelmer lexaptepid pegol in healthy subjects","volume":"173","author":"Boyce","year":"2016","journal-title":"Br J Pharmacol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"3847","DOI":"10.1158\/1538-7445.AM2014-3847","article-title":"Abstract 3847: The anti-hepcidin Spiegelmer\u00ae Lexaptepid Pegol (NOX-H94) as treatment of anemia of chronic disease in patients with multiple myeloma, low grade lymphoma, and CLL: A phase II pilot study","volume":"74","author":"Georgiev","year":"2014","journal-title":"Cancer Res"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.232124","article-title":"Iron metabolism and iron disorders revisited in the hepcidin era","volume":"105","author":"Camaschella","year":"2020","journal-title":"Haematologica"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.12.034","article-title":"A red carpet for iron metabolism","volume":"168","author":"Muckenthaler","year":"2017","journal-title":"Cell"},{"key":"B94","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1182\/blood-2010-06-289082","article-title":"Heparin: a potent inhibitor of hepcidin expression in vitro and in vivo","volume":"117","author":"Poli","year":"2011","journal-title":"Blood"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-07-515221","article-title":"Glycol-split nonanticoagulant heparins are inhibitors of hepcidin expression in vitro and in vivo","volume":"123","author":"Poli","year":"2014","journal-title":"Blood"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2014.09.007","article-title":"Oversulfated heparins with low anticoagulant activity are strong and fast inhibitors of hepcidin expression in vitro and in vivo","volume":"92","author":"Poli","year":"2014","journal-title":"Biochem Pharmacol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"173958","DOI":"10.1016\/j.ejphar.2021.173958","article-title":"Low anticoagulant heparin-iron complex targeting inhibition of hepcidin ameliorates anemia of chronic disease in rodents","volume":"897","author":"Li","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004653","article-title":"A fully human anti-BMP6 antibody reduces the need for erythropoietin in rodent models of the anemia of chronic disease","volume":"136","author":"Petzer","year":"2020","journal-title":"Blood"},{"key":"B99","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nchembio.2007.54","article-title":"Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism","volume":"4","author":"Yu","year":"2008","journal-title":"Nat Chem Biol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.3433.3433","article-title":"LY2928057, an antibody targeting ferroportin, is a potent inhibitor of hepcidin activity and increases iron mobilization in normal cynomolgus monkeys","volume":"122","author":"Witcher","year":"2013","journal-title":"Blood"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1124\/mol.112.083428","article-title":"High-throughput screening of small molecules identifies hepcidin antagonists","volume":"83","author":"Fung","year":"2013","journal-title":"Mol Pharmacol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-740092","article-title":"Momelotinib inhibits ACVR1\/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents","volume":"129","author":"Asshoff","year":"2017","journal-title":"Blood"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.282612","article-title":"Momelotinib (JAK1\/JAK2\/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis","volume":"108","author":"Tefferi","year":"2023","journal-title":"Haematologica"},{"key":"B104","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3390\/cancers16010154","article-title":"ACVR1: A novel therapeutic target to treat anemia in myelofibrosis","volume":"16","author":"Duminuco","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B105","doi-asserted-by":"publisher","first-page":"107877","DOI":"10.1016\/j.pharmthera.2021.107877","article-title":"Effect of hepcidin antagonists on anemia during inflammatory disorders","volume":"226","author":"Sagar","year":"2021","journal-title":"Pharmacol Ther"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-189985","article-title":"Involvement of oxygen-sensing pathways in physiologic and pathologic erythropoiesis","volume":"114","author":"Semenza","year":"2009","journal-title":"Blood"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0000000000000494","article-title":"New insights into the links between hypoxia and iron homeostasis","volume":"26","author":"Renassia","year":"2019","journal-title":"Curr Opin Hematol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s00228-020-03037-1","article-title":"Effectiveness of hypoxia-induced factor prolyl hydroxylase inhibitor for managing anemia in chronic kidney disease: a systematic review and meta-analysis","volume":"77","author":"Li","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.34.24147","article-title":"Identification of a hypoxia response element in the transferrin receptor gene","volume":"274","author":"Lok","year":"1999","journal-title":"J Biol Chem"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.22485","article-title":"Divalent metal transporter 1 is a hypoxia-inducible gene","volume":"226","author":"Qian","year":"2011","journal-title":"J Cell Physiol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.03.007","article-title":"Hypoxia-inducible factor-2\u03b1 mediates the adaptive increase of intestinal ferroportin during iron deficiency in mice","volume":"140","author":"Taylor","year":"2011","journal-title":"Gastroenterology"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2016.07.019","article-title":"Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease","volume":"90","author":"Pergola","year":"2016","journal-title":"Kidney Int"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901713","article-title":"Roxadustat treatment for anemia in patients undergoing long-term dialysis","volume":"381","author":"Chen","year":"2019","journal-title":"New Engl J Med"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813599","article-title":"Roxadustat for anemia in patients with kidney disease not receiving dialysis","volume":"381","author":"Chen","year":"2019","journal-title":"New Engl J Med"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26397","article-title":"Roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndrome: Open-label, dose-selection, lead-in stage of a phase 3 study","volume":"97","author":"Henry","year":"2022","journal-title":"Am J Hematol"},{"key":"B116","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1182\/blood-2023-180749","article-title":"Efficacy and safety of roxadustat for treatment of anemia in patients with lower-risk myelodysplastic syndrome (LR-MDS) with low red blood cell (RBC) transfusion burden: results of phase III matterhorn study","volume":"142","author":"Mittelman","year":"2023","journal-title":"Blood"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26865","article-title":"Open-label, Phase 2 study of roxadustat for the treatment of anemia in patients receiving chemotherapy for non-myeloid Malignancies","volume":"98","author":"Glaspy","year":"2023","journal-title":"Am J Hematol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1380358\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T01:02:15Z","timestamp":1712019735000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1380358\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,2]]},"references-count":117,"alternative-id":["10.3389\/fonc.2024.1380358"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1380358","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,2]]},"article-number":"1380358"}}